Revenue and EPS Growth
Total revenue grew 8% year-over-year in Q1 2026 and adjusted EPS was $0.77, up 7% year-over-year, reflecting a solid start to the year and execution against expectations.
Strong PST Performance
PST orders were up 6% year-over-year with a book-to-bill of 1.04x; Q1 organic revenue for PST finished up 4% and adjusted EBITDA was $122 million, up 15% year-over-year with adjusted EBITDA margins improving ~120 basis points.
Orders, Backlog and Book-to-Bill
Enterprise orders increased 5% year-over-year with a company-wide book-to-bill of 1.07x (ITS 1.08x), and management noted backlog strength from 2025 supporting expected second-half growth.
Free Cash Flow and Balance Sheet Strength
Q1 free cash flow was $163 million in line with expectations, the company has nearly $4 billion of total liquidity, leverage remains well below 2x, and management expects ~95% free cash flow to adjusted net income conversion for the year.
Robust M&A Pipeline and Strategic Acquisitions
Over 200 companies in the acquisition funnel with 10 LOIs and ~90% internally sourced; signed Fox s.r.l. (hydropneumatic accumulators) and expecting 400–500 basis points of annualized inorganic revenue in 2026 (~4–5%).
Notable Commercial Wins and Life Sciences Strength
Life Sciences orders grew double-digits in Q1 with strong integration wins (e.g., ILC Dover collaboration and a large carbon capture vacuum/blower application); management reports improving visibility and positive funnel activity in Life Sciences and short-cycle businesses.
Guidance Reaffirmed
Full-year 2026 guidance reaffirmed: revenue growth expected 2.5%–4.5% (midpoint organic growth ~1%), adjusted EBITDA $2.13B–$2.19B, adjusted EPS $3.45–$3.57 (~5% growth at midpoint), and no net tariff/inflation impact expected to guidance today.